{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:24:41Z","timestamp":1789525481007,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Background<\/jats:italic>\n                    Side effects of cancer therapy are one of the most important issues faced by cancer patients during their illness. Pharmacovigilance, namely the science and activities aimed at monitoring the safety of drugs, is particularly important in oncology, due to the intrinsic biologic toxicity of antineoplastic agents, their narrow therapeutic windows, and the high doses and rigid timing of treatment regimens.\n                    <jats:italic>Aim of the review<\/jats:italic>\n                    To identify the main issues in carrying out an effective pharmacovigilance activity in oncology.\n                    <jats:italic>Method<\/jats:italic>\n                    We searched PubMed for articles about pharmacovigilance in relation to chemotherapy, radiotherapy and targeted therapy for cancer, using MeSH terms and text words. We also searched Embase, CINAHL, Scopus, Micromedex, the Cochrane Library, two pharmacovigilance databases and the gray literature for articles published in 2012\u20132018. Overall, 137 articles were considered potentially relevant and were critically appraised independently by two authors, leading to the inclusion of 44 relevant studies, guidelines and reviews. Another 10 important research reports were included in the review.\n                    <jats:italic>Results<\/jats:italic>\n                    Eight critical issues of pharmacovigilance in oncology were identified. These issues pertain to: terminology; range of side effects; targeted therapy and immunotherapy; chemoradiotherapy; generic drugs and biosimilars; drug interactions, pharmacogenetics and polypharmacy; special patient categories; and under-reporting of ADRs.\n                    <jats:italic>Conclusion<\/jats:italic>\n                    The importance of pharmacovigilance in oncology must be highlighted with every effort, to improve safety and offer cancer patients every possible help to improve their quality of life during such a critical period of their lives.\n                  <\/jats:p>","DOI":"10.1007\/s11096-018-0706-9","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T03:09:45Z","timestamp":1533092985000},"page":"832-841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Pharmacovigilance in oncology"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5106-7120","authenticated-orcid":false,"given":"Paolo","family":"Baldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fornasier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ciolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Francescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"706_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0657-1","author":"G Fornasier","year":"2018","unstructured":"Fornasier G, Francescon S, Leone R, Baldo P. An historical overview over pharmacovigilance. Int J Clin Pharm. 2018. https:\/\/doi.org\/10.1007\/s11096-018-0657-1.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"706_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1586\/17512433.2015.974555","volume":"8","author":"M Tuccori","year":"2015","unstructured":"Tuccori M, Montagnani S, Capogrosso-Sansone A, Mantarro S, Antonioli L, Fornai M, et al. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Rev Clin Pharmacol. 2015;8(1):61\u201375.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"706_CR3","first-page":"626","volume":"12","author":"PM Lau","year":"2004","unstructured":"Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer. 2004;12(9):626\u201333.","journal-title":"Support Care Cancer"},{"key":"706_CR4","unstructured":"Welcome to Netherlands pharmacovigilance centre Lareb [Internet]. https:\/\/www.lareb.nl\/en\/. Accessed 21 Jan 2018."},{"issue":"5","key":"706_CR5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/pds.3375","volume":"22","author":"JL Oliveira","year":"2013","unstructured":"Oliveira JL, Lopes P, Nunes T, Campos D, Boyer S, Ahlberg E, et al. The EU-ADR Web Platform: delivering advanced pharmacovigilance tools. Pharmacoepidemiol Drug Saf. 2013;22(5):459\u201367.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"706_CR6","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Common Terminology Criteria for Adverse Events (CTCAE). Protocol Development. CTEP [Internet]. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed 18 Jan 2018."},{"key":"706_CR7","unstructured":"MedDRA [Internet]. https:\/\/www.meddra.org\/. Accessed 18 Jan 2018."},{"key":"706_CR8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","volume":"35","author":"PG Kluetz","year":"2016","unstructured":"Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016;35:67\u201373.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"706_CR9","doi-asserted-by":"crossref","first-page":"e0184360","DOI":"10.1371\/journal.pone.0184360","volume":"12","author":"A Pearce","year":"2017","unstructured":"Pearce A, Haas M, Viney R, Pearson S-A, Haywood P, Brown C, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study. PLoS ONE. 2017;12(10):e0184360.","journal-title":"PLoS ONE"},{"issue":"Suppl 7","key":"706_CR10","doi-asserted-by":"crossref","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155\u201366.","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"706_CR11","doi-asserted-by":"crossref","first-page":"v139","DOI":"10.1093\/annonc\/mdv202","volume":"26","author":"DE Peterson","year":"2015","unstructured":"Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J. ESMO Guidelines Committee. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015;26(Suppl 5):v139\u201351.","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"706_CR12","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(Suppl 5):v119\u201333.","journal-title":"Ann Oncol"},{"issue":"Suppl 7","key":"706_CR13","doi-asserted-by":"crossref","first-page":"vii139","DOI":"10.1093\/annonc\/mds233","volume":"23","author":"CI Ripamonti","year":"2012","unstructured":"Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F. ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii139\u201354.","journal-title":"Ann Oncol"},{"issue":"9","key":"706_CR14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","volume":"6","author":"K Imai","year":"2006","unstructured":"Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6(9):714\u201327.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"706_CR15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"25","key":"706_CR16","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2015.61.7613","volume":"33","author":"P Baldo","year":"2015","unstructured":"Baldo P, Fornasier G, Francescon S, Ferrarin E, Truccolo I, De Paoli P. Toxicities and adverse drug reactions experienced during anticancer treatment: it is desirable to consider the problem within the international system of pharmacovigilance. J Clin Oncol. 2015;33(25):2824\u20135.","journal-title":"J Clin Oncol"},{"issue":"2","key":"706_CR17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2010.31.9624","volume":"29","author":"B Seruga","year":"2011","unstructured":"Seruga B, Sterling L, Wang L, Tannock IF. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol. 2011;29(2):174\u201385.","journal-title":"J Clin Oncol"},{"issue":"2","key":"706_CR18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1368-8375(02)00033-7","volume":"39","author":"A Barasch","year":"2003","unstructured":"Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003;39(2):91\u2013100.","journal-title":"Oral Oncol"},{"issue":"1","key":"706_CR19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","volume":"21","author":"F Kroschinsky","year":"2017","unstructured":"Kroschinsky F, St\u00f6lzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care Lond Engl. 2017;21(1):89.","journal-title":"Crit Care Lond Engl"},{"issue":"26","key":"706_CR20","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"},{"issue":"18","key":"706_CR21","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","volume":"33","author":"JS Weber","year":"2015","unstructured":"Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"706_CR22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cpt.404","volume":"100","author":"JS McCune","year":"2016","unstructured":"McCune JS. Immunotherapy to treat cancer. Clin Pharmacol Ther. 2016;100(3):198\u2013203.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"706_CR23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40257-016-0186-4","volume":"17","author":"M Singh","year":"2016","unstructured":"Singh M, Alavi A, Wong R, Akita S. Radiodermatitis: a review of our current understanding. Am J Clin Dermatol. 2016;17(3):277\u201392.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"706_CR24","first-page":"199","volume":"20","author":"M Biedka","year":"2016","unstructured":"Biedka M, Ku\u017aba-Kryszak T, Nowikiewicz T, \u017byromska A. Fertility impairment in radiotherapy. Contemp Oncol Pozn Pol. 2016;20(3):199\u2013204.","journal-title":"Contemp Oncol Pozn Pol"},{"issue":"5","key":"706_CR25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/jrr\/rrw064","volume":"57","author":"S Tapio","year":"2016","unstructured":"Tapio S. Pathology and biology of radiation-induced cardiac disease. J Radiat Res. 2016;57(5):439\u201348.","journal-title":"J Radiat Res"},{"issue":"12","key":"706_CR26","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","volume":"25","author":"DC Hodgson","year":"2007","unstructured":"Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma. J Clin Oncol. 2007;25(12):1489\u201397.","journal-title":"J Clin Oncol"},{"issue":"11","key":"706_CR27","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(16)30384-9","volume":"17","author":"YT Yang","year":"2016","unstructured":"Yang YT, Nagai S, Chen BK, Qureshi ZP, Lebby AA, Kessler S, et al. Generic oncology drugs: are they all safe? Lancet Oncol. 2016;17(11):e493\u2013501.","journal-title":"Lancet Oncol"},{"issue":"4","key":"706_CR28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40262-016-0450-z","volume":"56","author":"D Bertholee","year":"2017","unstructured":"Bertholee D, Maring JG, van Kuilenburg ABP. Genotypes affecting the pharmacokinetics of anticancer drugs. Clin Pharmacokinet. 2017;56(4):317\u201337.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"706_CR29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2125.2006.02744.x","volume":"63","author":"KK Viktil","year":"2007","unstructured":"Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(2):187\u201395.","journal-title":"Br J Clin Pharmacol"},{"key":"706_CR30","unstructured":"Cooper JA, Cadogan CA, Patterson SM, Kerse N, Bradley MC, Ryan C, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open [Internet]. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4679890\/. Accessed 21 Jan 2018."},{"issue":"5","key":"706_CR31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7861\/clinmedicine.16-5-465","volume":"16","author":"RA Payne","year":"2016","unstructured":"Payne RA. The epidemiology of polypharmacy. Clin Med Lond Engl. 2016;16(5):465\u20139.","journal-title":"Clin Med Lond Engl"},{"issue":"3","key":"706_CR32","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1634\/theoncologist.2016-0208","volume":"22","author":"SS Shachar","year":"2017","unstructured":"Shachar SS, Gallagher K, McGuire K, Zagar TM, Faso A, Muss HB, et al. Multidisciplinary management of breast cancer during pregnancy. Oncologist. 2017;22(3):324\u201334.","journal-title":"Oncologist"},{"issue":"5","key":"706_CR33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1470-2045(04)01466-4","volume":"5","author":"E Cardonick","year":"2004","unstructured":"Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5(5):283\u201391.","journal-title":"Lancet Oncol"},{"issue":"7216","key":"706_CR34","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","volume":"278","author":"WG Mcbride","year":"1961","unstructured":"Mcbride WG. Thalidomide and congenital abnormalities. Lancet. 1961;278(7216):1358.","journal-title":"Lancet"},{"issue":"6478","key":"706_CR35","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.290.6478.1355","volume":"290","author":"WH Inman","year":"1985","unstructured":"Inman WH. Under-reporting of adverse drug reactions. Br Med J Clin Res Ed. 1985;290(6478):1355.","journal-title":"Br Med J Clin Res Ed"},{"issue":"2","key":"706_CR36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-012-1321-7","volume":"69","author":"C Biagi","year":"2013","unstructured":"Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2013;69(2):237\u201344.","journal-title":"Eur J Clin Pharmacol"},{"key":"706_CR37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jflm.2015.05.015","volume":"34","author":"RK Sewal","year":"2015","unstructured":"Sewal RK, Saini VK, Medhi B. Forensic pharmacovigilance: newer dimension of pharmacovigilance. J Forensic Leg Med. 2015;34:113\u20138.","journal-title":"J Forensic Leg Med"},{"issue":"9","key":"706_CR38","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.2196\/resprot.6463","volume":"6","author":"C Bousquet","year":"2017","unstructured":"Bousquet C, Dahamna B, Guillemin-Lanne S, Darmoni SJ, Faviez C, Huot C, et al. The adverse drug reactions from patient reports in social media project: five major challenges to overcome to operationalize analysis and efficiently support pharmacovigilance process. JMIR Res Protoc. 2017;6(9):e179.","journal-title":"JMIR Res Protoc"},{"key":"706_CR39","unstructured":"After Diagnosis [Internet]. https:\/\/www.cancer.org\/treatment\/understanding-your-diagnosis\/after-diagnosis.html. Accessed 21 Jan 2018."},{"key":"706_CR40","unstructured":"European Medicines Agency - Pharmacovigilance - Legal framework [Internet]. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/general\/general_content_000491.jsp&mid=WC0b01ac058058f32d. Accessed 28 Jun 2018."},{"issue":"12","key":"706_CR41","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.clinthera.2016.11.007","volume":"38","author":"J Wu","year":"2016","unstructured":"Wu J, Juhaeri J. The US Food and Drug Administration\u2019s Risk Evaluation and Mitigation Strategy (REMS) Program\u2014current status and future direction. Clin Ther. 2016;38(12):2526\u201332.","journal-title":"Clin Ther"},{"issue":"2","key":"706_CR42","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1200\/JOP.2012.000620","volume":"9","author":"JN Frame","year":"2013","unstructured":"Frame JN, Jacobson JO, Vogel WH, Griffith N, Wariabharaj D, Garg R, et al. Assessment of risk evaluation and mitigation strategies in oncology: summary of the oncology risk evaluation and mitigation strategies workshop. J Oncol Pract. 2013;9(2):e24\u201339.","journal-title":"J Oncol Pract"},{"key":"706_CR43","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","volume":"359","author":"C Davis","year":"2017","unstructured":"Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009\u201313. BMJ. 2017;359:j4530.","journal-title":"BMJ"},{"issue":"8","key":"706_CR44","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ejim.2015.08.008","volume":"26","author":"R Banzi","year":"2015","unstructured":"Banzi R, Gerardi C, Bertele\u2019 V, Garattini S. Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur J Intern Med. 2015;26(8):572\u201384.","journal-title":"Eur J Intern Med"},{"issue":"82","key":"706_CR45","first-page":"66","volume":"2017","author":"N Gr\u00f6ssmann","year":"1990","unstructured":"Gr\u00f6ssmann N, Del Paggio JC, Wolf S, Sullivan R, Booth CM, Rosian K, et al. Five years of EMA-approved systemic cancer therapies for solid tumours\u2014a comparison of two thresholds for meaningful clinical benefit. Eur J Cancer Oxf Engl. 1990;2017(82):66\u201371.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"706_CR46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jbi.2015.02.004","volume":"54","author":"A Sarker","year":"2015","unstructured":"Sarker A, Ginn R, Nikfarjam A, O\u2019Connor K, Smith K, Jayaraman S, et al. Utilizing social media data for pharmacovigilance: a review. J Biomed Inform. 2015;54:202\u201312.","journal-title":"J Biomed Inform"},{"key":"706_CR47","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2147\/TCRM.S137144","volume":"13","author":"A Arora","year":"2017","unstructured":"Arora A, Jalali RK, Vohora D. Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. Ther Clin Risk Manag. 2017;13:1195\u2013203.","journal-title":"Ther Clin Risk Manag"},{"issue":"Suppl_4","key":"706_CR48","doi-asserted-by":"crossref","first-page":"S399","DOI":"10.1093\/infdis\/jiw281","volume":"214","author":"M Salath\u00e9","year":"2016","unstructured":"Salath\u00e9 M. Digital pharmacovigilance and disease surveillance: combining traditional and big-data systems for better public health. J Infect Dis. 2016;214(Suppl_4):S399\u2013403.","journal-title":"J Infect Dis"},{"issue":"11","key":"706_CR49","doi-asserted-by":"crossref","first-page":"djx187","DOI":"10.1093\/jnci\/djx187","volume":"109","author":"S Khozin","year":"2017","unstructured":"Khozin S, Blumenthal GM, Pazdur R. Real-world data for clinical evidence generation in oncology. J Natl Cancer Inst. 2017;109(11):djx187.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"706_CR50","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12885-017-3303-8","volume":"17","author":"K Absolom","year":"2017","unstructured":"Absolom K, Holch P, Warrington L, Samy F, Hulme C, Hewison J, et al. Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID): a randomised controlled trial in systemic cancer treatment. BMC Cancer. 2017;17(1):318.","journal-title":"BMC Cancer"},{"issue":"6","key":"706_CR51","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1200\/JCO.2017.75.8193","volume":"36","author":"LA Levit","year":"2018","unstructured":"Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM. Streamlining adverse events reporting in oncology: an American Society of Clinical Oncology Research Statement. J Clin Oncol. 2018;36(6):617\u201323.","journal-title":"J Clin Oncol"},{"issue":"72","key":"706_CR52","first-page":"71","volume":"2017","author":"A Linker","year":"1990","unstructured":"Linker A, Yang A, Roper N, Whitaker E, Korenstein D. Impact of industry collaboration on randomised controlled trials in oncology. Eur J Cancer Oxf Engl. 1990;2017(72):71\u20137.","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"61","key":"706_CR53","first-page":"29","volume":"2016","author":"FE Vera-Badillo","year":"1990","unstructured":"Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SMH, Chan A-W, Ocana A, et al. Bias in reporting of randomised clinical trials in oncology. Eur J Cancer Oxf Engl. 1990;2016(61):29\u201335.","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"5","key":"706_CR54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clgc.2014.04.001","volume":"12","author":"JN Ruiz","year":"2014","unstructured":"Ruiz JN, Belum VR, Creel P, Cohn A, Ewer M, Lacouture ME. Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists. Clin Genitourin Cancer. 2014;12(5):341\u20137.","journal-title":"Clin Genitourin Cancer"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-018-0706-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0706-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0706-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T19:50:22Z","timestamp":1613591422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-018-0706-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1007\/s11096-018-0706-9","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"30 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}